Ryboquin Ltd., of Selkirk, U.K., acquired Nanogenic Solutions LLC, of Union City, Calif., to form a new product and platform company, Nanogenics Ltd., and advance gene therapies. Nanogenics is developing Liptide, an artificial virus, which acts as a custom-built delivery system that can be modified to target different cell types and deliver different payloads, making the promise of gene therapy one step closer to reality, the companies said. Terms were not disclosed.